Novo Nordisk
NVO
#21
Rank
NZ$785.11 B
Marketcap
$172.96
Share price
-3.54%
Change (1 day)
4.69%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$14.52 Billion

According to Novo Nordisk's latest financial reports the company's total debt is NZ$14.52 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$6.32 B8.14%
2022-12-31NZ$5.84 B-1.53%
2021-12-31NZ$5.93 B150.33%
2020-12-31NZ$2.37 B137.71%
2019-12-31NZ$0.99 B748.44%
2018-12-31NZ$0.11 B-69.41%
2017-12-31NZ$0.38 B721.49%
2016-12-31NZ$46.8 M-79.63%
2015-12-31NZ$0.22 B53.08%
2014-12-31NZ$0.15 B209.85%
2013-12-31NZ$48.43 M-55.05%
2012-12-31NZ$0.10 B-43.4%
2011-12-31NZ$0.19 B-62.99%
2010-12-31NZ$0.51 B39.75%
2009-12-31NZ$0.36 B-51%
2008-12-31NZ$0.75 B115.34%
2007-12-31NZ$0.34 B-8.47%
2006-12-31NZ$0.38 B-38.88%
2005-12-31NZ$0.62 B43.21%
2004-12-31NZ$0.43 B-3.4%
2003-12-31NZ$0.45 B18.27%
2002-12-31NZ$0.38 B-34.77%
2001-12-31NZ$0.58 B2.05%
2000-12-31NZ$0.57 B3.87%
1999-12-31NZ$0.55 B-26.74%
1998-12-31NZ$0.75 B-2.14%
1997-12-31NZ$0.76 B64.43%
1996-12-31NZ$0.46 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$113.40 B 680.55%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$52.97 B 264.63%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$87.50 B 502.25%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$43.34 B 198.32%๐Ÿ‡ซ๐Ÿ‡ท France